Botanix Pharmaceuticals Ltd (ASX:BOT) recently saw 1 million shares purchased on market by its very own chairman – Graham Griffiths.
Botanix is a medical dermatology company developing treatments for serious skin diseases and its board and management own over 23% of the company.
One such skin disease is acne, affecting 50 million people creating a market valued near $3 billion.
By harnessing the ingredient cannabidiol, Botanix is preparing for the first human trials utilising its proprietary drug Permetrex™.
The company recently presented at the 7th Annual Australian Microcap Investment Conference where it exhibited why it might have the holy grail of acne treatments.
Botanix listed on the ASX in July 2016 by way of reverse takeover – shares are now trading more than double the prospectus offering price of $0.02.